Foghorn Therapeutics Inc. Income Statement
FHTX|6 years of annual SEC 10-K data (FY2020-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 6 fiscal years. All figures from audited SEC 10-K filings.
Foghorn Therapeutics Inc. reported $23M in revenue and $87M in net loss for FY2025. Revenue has grown at a 120.9% compound annual rate over the past 5 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score -1.20 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $22.6M | $34.2M | $19.2M | $1.3M | $430.0K | $430.0K |
| SG&A Expense | $28.4M | $32.4M | $30.7M | $21.7M | $11.2M | $6.7M |
| R&D Expense | $94.5M | $109.7M | $105.6M | $80.3M | $57.7M | $44.4M |
| Operating Income | -$102.7M | -$107.9M | -$117.1M | -$100.7M | -$68.5M | -$51.1M |
| Interest Expense | - | - | - | - | $979.0K | $540.0K |
| Income Tax | $0 | $4.2M | $0 | - | - | $0 |
| Net Income | -$86.6M | -$98.4M | -$108.9M | -$101.3M | -$68.8M | -$51.1M |
| EPS (Basic) | -$1.58 | -$2.34 | -$2.62 | -$2.73 | -$6.23 | - |
| EPS (Diluted) | -$1.58 | -$2.34 | -$2.62 | -$2.73 | -$6.23 | -$12.20 |
| Shares Outstanding | 55.6M | 42.3M | 41.8M | 41.3M | 36.8M | 4.9M |
| Operating Margin | -454.3% | -315.9% | -609.2% | -7637.1% | -15937.4% | -11880.0% |
| Profit Margin | -383.2% | -288.2% | -566.3% | -7681.6% | -16000.0% | -11890.2% |